



US007236830B2

(12) **United States Patent**
Gliner

(10) **Patent No.:** **US 7,236,830 B2**

(45) **Date of Patent:** **Jun. 26, 2007**

(54) **SYSTEMS AND METHODS FOR
ENHANCING OR OPTIMIZING NEURAL
STIMULATION THERAPY FOR TREATING
SYMPTOMS OF PARKINSON'S DISEASE
AND/OR OTHER MOVEMENT DISORDERS**

| | | |
|-------------|---------|----------------|
| 4,590,946 A | 5/1986 | Loeb |
| 4,607,639 A | 8/1986 | Tanagho et al. |
| 4,646,744 A | 3/1987 | Capel |
| 4,844,075 A | 7/1989 | Liss et al. |
| 4,865,048 A | 9/1989 | Eckerson |
| 4,969,468 A | 11/1990 | Byers et al. |

(75) Inventor: **Bradford Evan Gliner**, Sammamish,
WA (US)

(Continued)

(73) Assignee: **Northstar Neuroscience, Inc.**, Seattle,
WA (US)

FOREIGN PATENT DOCUMENTS

DE 19750043 5/1999

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 371 days.

(Continued)

OTHER PUBLICATIONS

(21) Appl. No.: **10/317,002**

Tsubokawa, T. et al., "Chronic Motor Cortex Stimulation for the
Treatment of Central Pain", Acta Neurochirurgica, Suppl. 52, pp.
137-139 (1991).

(22) Filed: **Dec. 10, 2002**

(Continued)

(65) **Prior Publication Data**

US 2004/0111127 A1 Jun. 10, 2004

Primary Examiner—Scott M. Getzow

(74) Attorney, Agent, or Firm—Perkins Coie LLP

(51) **Int. Cl.**
A61N 1/00 (2006.01)

(57) **ABSTRACT**

(52) **U.S. Cl.** **607/45**

(58) **Field of Classification Search** **607/45**
See application file for complete search history.


Systems and methods for treating a neurological disorder comprising determining a first set of neural stimulation parameters capable of treating a first subset of symptoms, determining a second set of neural stimulation parameters capable of treating a second subset of symptoms, and applying a neural stimulation therapy based upon the first set of neural stimulation parameters and the second set of neural stimulation parameters to the patient. The first set of neural stimulation parameters can include electrical stimulation at a first frequency, and the second set of neural stimulation parameters can include electrical stimulation at a second frequency. In other embodiments, a treatment method comprises applying a first neural stimulation therapy to the patient in a continuous or generally continuous manner during a first time interval, and applying a second neural stimulation therapy to the patient in a noncontinuous or interrupted manner following the first time interval.

(56) **References Cited**

U.S. PATENT DOCUMENTS

| | | |
|-------------|---------|-------------------|
| 2,721,316 A | 10/1955 | Shaw |
| 3,628,193 A | 12/1971 | Collins |
| 3,650,276 A | 3/1972 | Burghele et al. |
| 4,030,509 A | 6/1977 | Heilman et al. |
| 4,125,116 A | 11/1978 | Fischell |
| 4,140,133 A | 2/1979 | Kastrubin et al. |
| 4,214,804 A | 7/1980 | Little |
| 4,245,645 A | 1/1981 | Arseneault et al. |
| 4,328,813 A | 5/1982 | Ray |
| 4,340,038 A | 7/1982 | McKean |
| 4,431,000 A | 2/1984 | Butler et al. |
| 4,474,186 A | 10/1984 | Ledley et al. |
| 4,542,752 A | 9/1985 | DeHaan et al. |

12 Claims, 6 Drawing Sheets



| U.S. PATENT DOCUMENTS | | | |
|-----------------------|---------|--------------------|--|
| 5,002,053 A | 3/1991 | Garcia-Rill et al. | 5,941,906 A 8/1999 Barreras, Sr. et al. |
| 5,024,226 A | 6/1991 | Tan | 5,964,794 A 10/1999 Bolz et al. |
| 5,031,618 A | 7/1991 | Mullett | 5,975,085 A 11/1999 Rise |
| 5,054,906 A | 10/1991 | Lyons, Jr. | 5,978,702 A 11/1999 Ward et al. |
| 5,063,932 A | 11/1991 | Dahl et al. | 5,983,140 A 11/1999 Smith et al. |
| 5,092,835 A | 3/1992 | Schurig et al. | 6,006,124 A 12/1999 Fischell et al. |
| 5,121,754 A | 6/1992 | Mullett | 6,011,996 A 1/2000 Gielen et al. |
| 5,143,089 A | 9/1992 | Alt | 6,016,449 A 1/2000 Fischell et al. |
| 5,169,384 A | 12/1992 | Bosniak et al. | 6,021,352 A 2/2000 Christopherson et al. |
| 5,184,620 A | 2/1993 | Cudahy et al. | 6,026,326 A 2/2000 Bardy |
| 5,215,086 A | 6/1993 | Terry, Jr. et al. | 6,035,236 A 3/2000 Jardine et al. |
| 5,224,491 A | 7/1993 | Mehra | 6,042,579 A 3/2000 Elsberry et al. |
| 5,255,678 A | 10/1993 | Deslauriers et al. | 6,052,624 A 4/2000 Mann |
| 5,263,967 A | 11/1993 | Lyons, III et al. | 6,055,456 A 4/2000 Gerber |
| 5,271,417 A | 12/1993 | Swanson et al. | 6,057,847 A 5/2000 Jenkins |
| 5,282,468 A | 2/1994 | Klepinski | 6,058,331 A 5/2000 King |
| 5,299,569 A | 4/1994 | Wernicke et al. | 6,060,048 A 5/2000 Cherksey |
| 5,304,206 A | 4/1994 | Baker, Jr. et al. | 6,061,593 A 5/2000 Fischell et al. |
| 5,314,458 A | 5/1994 | Najafi et al. | 6,066,163 A 5/2000 John |
| 5,358,513 A | 10/1994 | Powell, III et al. | 6,104,956 A 8/2000 Naritoku et al. |
| 5,370,672 A | 12/1994 | Fowler et al. | 6,104,960 A 8/2000 Duysens et al. |
| 5,405,375 A | 4/1995 | Ayers et al. | 6,122,548 A 9/2000 Starkebaum et al. |
| 5,406,957 A | 4/1995 | Tansey | 6,126,657 A 10/2000 Edwards et al. |
| 5,411,540 A | 5/1995 | Edell et al. | 6,128,537 A 10/2000 Rise |
| 5,417,719 A | 5/1995 | Hull et al. | 6,128,538 A 10/2000 Fischell et al. |
| 5,423,864 A | 6/1995 | Ljungstroem | 6,134,474 A 10/2000 Fischell et al. |
| 5,464,446 A | 11/1995 | Dreessen et al. | 6,152,143 A 11/2000 Edwards |
| 5,520,190 A | 5/1996 | Benedict et al. | 6,161,044 A 12/2000 Silverstone |
| 5,522,864 A | 6/1996 | Wallace et al. | 6,161,045 A 12/2000 Fischell et al. |
| 5,537,512 A | 7/1996 | Hsia et al. | 6,176,242 B1 1/2001 Rise |
| 5,540,736 A | 7/1996 | Haimovich et al. | 6,198,958 B1 3/2001 Ives et al. |
| 5,549,655 A | 8/1996 | Erickson | 6,205,360 B1 3/2001 Carter et al. |
| 5,562,708 A | 10/1996 | Combs et al. | 6,210,417 B1 4/2001 Baudino et al. |
| 5,575,813 A | 11/1996 | Edell et al. | 6,221,908 B1 4/2001 Kilgard et al. |
| 5,591,216 A | 1/1997 | Testerman et al. | 6,230,049 B1 5/2001 Fischell et al. |
| 5,593,432 A | 1/1997 | Crowther et al. | 6,236,892 B1 5/2001 Feler |
| 5,601,611 A | 2/1997 | Fayram et al. | 6,246,912 B1 6/2001 Sluijter et al. |
| 5,628,317 A | 5/1997 | Starkebaum et al. | 6,280,462 B1 8/2001 Hauser et al. |
| 5,674,251 A | 10/1997 | Combs et al. | 6,301,493 B1 10/2001 Marro et al. |
| 5,676,655 A | 10/1997 | Howard, III et al. | 6,339,725 B1 1/2002 Naritoku et al. |
| 5,683,422 A | 11/1997 | Rise | 6,353,754 B1 3/2002 Fischell et al. |
| 5,702,429 A | 12/1997 | King | 6,354,299 B1 3/2002 Fischell et al. |
| 5,711,316 A | 1/1998 | Elsberry et al. | 6,356,792 B1 3/2002 Errico et al. |
| 5,713,922 A | 2/1998 | King | 6,360,122 B1 3/2002 Fischell et al. |
| 5,713,923 A | 2/1998 | Ward et al. | 6,366,813 B1 * 4/2002 DiLorenzo 607/45 |
| 5,716,377 A | 2/1998 | Rise et al. | 6,375,666 B1 4/2002 Mische |
| 5,722,401 A | 3/1998 | Pietroski et al. | 6,405,079 B1 6/2002 Ansarinia |
| 5,735,814 A | 4/1998 | Elsberry et al. | 6,418,344 B1 7/2002 Rezai et al. |
| 5,752,979 A | 5/1998 | Benabid | 6,427,086 B1 7/2002 Fischell et al. |
| 5,772,591 A | 6/1998 | Cram | 6,459,936 B2 10/2002 Fischell et al. |
| 5,782,798 A | 7/1998 | Rise | 6,463,328 B1 10/2002 John |
| 5,782,873 A | 7/1998 | Collins | 6,464,356 B1 10/2002 Sabel |
| 5,792,186 A | 8/1998 | Rise | 6,466,822 B1 10/2002 Pless |
| 5,797,970 A | 8/1998 | Pouvreau | 6,473,568 B2 10/2002 Kashiyama |
| 5,814,014 A | 9/1998 | Elsberry et al. | 6,473,639 B1 10/2002 Fischell et al. |
| 5,814,092 A | 9/1998 | King | 6,480,743 B1 11/2002 Kirkpatrick et al. |
| 5,824,021 A | 10/1998 | Rise | 6,484,059 B2 11/2002 Gielen |
| 5,824,030 A | 10/1998 | Yang et al. | 6,487,450 B1 11/2002 Chen |
| 5,832,932 A | 11/1998 | Elsberry et al. | 6,499,488 B1 12/2002 Hunter et al. |
| 5,833,709 A | 11/1998 | Rise et al. | 6,505,075 B1 1/2003 Weiner |
| 5,843,148 A | 12/1998 | Gijsbers et al. | 6,507,755 B1 1/2003 Gozani et al. |
| 5,843,150 A | 12/1998 | Dreessen et al. | 6,556,868 B2 4/2003 Naritoku et al. |
| 5,865,842 A | 2/1999 | Knuth et al. | 6,597,954 B1 7/2003 Pless et al. |
| 5,885,976 A | 3/1999 | Sandyk | 6,615,065 B1 9/2003 Barrett et al. |
| 5,886,769 A | 3/1999 | Zolten | 6,622,048 B1 9/2003 Mann et al. |
| 5,893,883 A | 4/1999 | Torgerson et al. | 6,633,780 B1 10/2003 Berger |
| 5,904,916 A | 5/1999 | Hirsch | 6,665,562 B2 12/2003 Gluckman et al. |
| 5,913,882 A | 6/1999 | King | 6,687,525 B2 2/2004 Llinas et al. |
| 5,925,070 A | 7/1999 | King et al. | 6,690,974 B2 2/2004 Archer et al. |
| 5,938,688 A | 8/1999 | Schiff | 6,725,094 B2 4/2004 Saberski |
| 5,938,689 A | 8/1999 | Fischell et al. | 6,764,498 B2 7/2004 Mische |
| | | | 6,782,292 B2 8/2004 Whitehurst |

| | | | |
|--------------|----|---------|------------------|
| 6,795,737 | B2 | 9/2004 | Gielen et al. |
| 6,810,286 | B2 | 10/2004 | Donovan et al. |
| 6,839,594 | B2 | 1/2005 | Cohen et al. |
| 6,873,872 | B2 | 3/2005 | Gluckman et al. |
| 6,892,097 | B2 | 5/2005 | Holsheimer |
| 6,895,280 | B2 | 5/2005 | Meadows et al. |
| 6,907,296 | B1 | 6/2005 | Doan et al. |
| 6,934,580 | B1 | 8/2005 | Osorio et al. |
| 6,944,497 | B2 | 9/2005 | Stypulkowski |
| 6,959,215 | B2 | 10/2005 | Gliner et al. |
| 6,990,377 | B2 | 1/2006 | Gliner et al. |
| 7,006,859 | B1 | 2/2006 | Osorio et al. |
| 7,010,351 | B2 | 3/2006 | Firlik et al. |
| 7,024,247 | B2 | 4/2006 | Gliner et al. |
| 7,110,820 | B2 | 9/2006 | Tcheng et al. |
| 2002/0077670 | A1 | 6/2002 | Archer et al. |
| 2002/0087201 | A1 | 7/2002 | Firlik |
| 2002/0091419 | A1 | 7/2002 | Firlik et al. |
| 2002/0099412 | A1 | 7/2002 | Fischell et al. |
| 2002/0169485 | A1 | 11/2002 | Pless et al. |
| 2003/0074032 | A1 | 4/2003 | Gliner |
| 2003/0078633 | A1 | 4/2003 | Firlik et al. |
| 2003/0088274 | A1 | 5/2003 | Gliner et al. |
| 2003/0097161 | A1 | 5/2003 | Firlik et al. |
| 2003/0125772 | A1 | 7/2003 | Olson et al. |
| 2003/0125786 | A1 | 7/2003 | Gliner et al. |
| 2003/0130706 | A1 | 7/2003 | Sheffield et al. |
| 2003/0149457 | A1 | 8/2003 | Tcheng et al. |
| 2003/0176901 | A1 | 9/2003 | May |
| 2003/0187490 | A1 | 10/2003 | Gliner |
| 2003/0187491 | A1 | 10/2003 | Greenberg et al. |
| 2004/0073270 | A1 | 4/2004 | Firlik et al. |
| 2004/0082847 | A1 | 4/2004 | McDermott |
| 2004/0092809 | A1 | 5/2004 | DeCharms |
| 2004/0102828 | A1 | 5/2004 | Lowry et al. |
| 2004/0138550 | A1 | 7/2004 | Hartlep et al. |
| 2004/0158298 | A1 | 8/2004 | Gliner et al. |
| 2004/0176831 | A1 | 9/2004 | Gliner et al. |
| 2004/0181263 | A1 | 9/2004 | Balzer et al. |
| 2004/0215287 | A1 | 10/2004 | Swoyer et al. |
| 2004/0236388 | A1 | 11/2004 | Gielen et al. |
| 2004/0243205 | A1 | 12/2004 | Keravel et al. |
| 2004/0249422 | A1 | 12/2004 | Gliner et al. |
| 2005/0004620 | A1 | 1/2005 | Singhal et al. |
| 2005/0015129 | A1 | 1/2005 | Mische |
| 2005/0021105 | A1 | 1/2005 | Firlik et al. |
| 2005/0021106 | A1 | 1/2005 | Firlik et al. |
| 2005/0021107 | A1 | 1/2005 | Firlik et al. |
| 2005/0021118 | A1 | 1/2005 | Genau et al. |
| 2005/0033378 | A1 | 2/2005 | Sheffield et al. |
| 2005/0070971 | A1 | 3/2005 | Fowler et al. |
| 2005/0075679 | A1 | 4/2005 | Gliner et al. |
| 2005/0075680 | A1 | 4/2005 | Lowry et al. |
| 2005/0096701 | A1 | 5/2005 | Donovan et al. |
| 2005/0113882 | A1 | 5/2005 | Cameron et al. |
| 2005/0119712 | A1 | 6/2005 | Shafer |
| 2005/0154425 | A1 | 7/2005 | Boveja et al. |
| 2005/0154426 | A1 | 7/2005 | Boveja et al. |
| 2006/0015153 | A1 | 1/2006 | Gliner et al. |
| 2006/0106430 | A1 | 5/2006 | Fowler et al. |
| 2006/0106431 | A1 | 5/2006 | Wylter et al. |
| 2006/0129205 | A1 | 6/2006 | Boveja et al. |
| 2006/0173522 | A1 | 8/2006 | Osorio |
| 2006/0217782 | A1 | 9/2006 | Boveja et al. |

FOREIGN PATENT DOCUMENTS

| | | | |
|----|-------------|----|---------|
| EP | 0319844 | A1 | 6/1989 |
| EP | 0 998 958 | A2 | 10/2000 |
| EP | 1 145 736 | | 10/2001 |
| EP | 1180056 | | 11/2003 |
| WO | WO-87/07511 | | 12/1987 |
| WO | WO-94/07564 | | 4/1994 |

| | | |
|----|--------------|-----------|
| WO | WO-95/21591 | 8/1995 |
| WO | WO-98/06342 | 2/1998 |
| WO | WO-01/97906 | 12/2001 |
| WO | WO-02/09811 | 2/2002 |
| WO | WO-02/36003 | 5/2002 |
| WO | WO-02/38031 | 5/2002 |
| WO | WO-02/38217 | 5/2002 |
| WO | WO-03/082402 | A2 3/2003 |
| WO | WO-03/043690 | 5/2003 |

OTHER PUBLICATIONS

- Meyerson, B.A. et al., "Motor Cortex Stimulation as Treatment of Trigeminal Neuropathic Pain", *Acta Neurochirurgica Supplementum*, vol. 58, pp. 150-153 (1993).
- Tsubokawa, T. et al., "Treatment of Thalamic Pain by Chronic Motor Cortex Stimulation", *PACE*, vol. 14, pp. 131-134 (Jan. 1991).
- Barr, Deborah et al., "Induction and Reversal of Long-Term Potentiation by Low- and High- Intensity Theta Pattern Stimulation," *The Journal of Neuroscience*, 15(7): pp. 5402-5410 (Jul. 1995).
- Behrens, T. et al., "Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging," *Nature Neuroscience*, vol. 6 No. 7, pp. 750-757 (Jul. 2003).
- Bel, S. and Bauer, B.L., "Dorsal Column Stimulation (DCS): Cost to Benefit Analysis," *Acta Neurochirurgica*, Suppl. 52, pp. 121-123 (1991).
- Benabid, A.L. et al., "Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders," *J. Neurosurg.*, Apr. 1997, 86(4); 737; <http://www.ncbi.nlm.nih.gov>; [accessed Nov. 18, 2003].
- Brain Electrical Stimulation to Enhance Recovery After Stroke. *BrainTrials.gov*. [Retrieved on Dec. 22, 2005]. Retrieved from the internet <URL <http://www.clinicaltrials.gov/ct/show/NCT00085657?order=2>>.
- Burnett, Mark G. et al., "Diffuse optical measurement of blood flow, blood oxygenation, and metabolism in a human brain during sensorimotor cortex activation," *Optics Letters*, vol. 29, No. 15, pp. 1766-1768 (Aug. 1, 2004).
- Butefisch et al., "Mechanisms of use-dependent plasticity in the human motor cortex," *Proc. Natl. Acad. Sci. USA*, vol. 97, No. 7, pp. 3661-3665 (Mar. 2000).
- Canavero, S. and Paolotti, R., "Extradural Motor Cortex Stimulation after Advanced Parkinson's Disease: Case Report," *Movement Disorders*, 15(1):169-171,2000.
- Cincotta et al., "Reorganization of the motor cortex in a patient with congenital hemiparesis and mirror movements," *Neurology*, vol. 55, pp. 129-131 (2000).
- Classen, et al., "Rapid Plasticity of Human Cortical Movement Representation Induced by Practice," *The Journal of Neurophysiology*, vol. 79, No. 2, pp. 1117-1123 (Feb. 1998).
- Cohen et al., "Studies of Neuroplasticity With Transcranial Magnetic Stimulation," *The Journal of Clinical Neurophysiology*, vol. 15, No. 4 (1998).
- Cramer, S.C. and Bastings, E.P., "Mapping clinically relevant plasticity after stroke," *Neuropharmacology* vol. 19, No. 5, pp. 842-851 (Apr. 2000).
- Cytokines Web Clinical Significance. Cytokines Web, 2 pages. [Retrieved on Sep. 2, 2005]. Retrieved from the internet: <URL: http://cmbi.bjmu.edu.cn/cmbidata/cgf/CGF_Database/cytweb/roles/index.html>.
- Dam et al., "Effects of Fluoxetine and Maprotiline on Functional Recovery in Poststroke Hemiplegic Patients Undergoing Rehabilitation Therapy," *Stroke*, vol. 27, No. 7, pp. 1211-1214 (Jul. 1996).
- De Ridder, Dirk et al., "Magnetic and electrical stimulation of the auditory cortex for intractable tinnitus," *Journal Neurosurg.*, vol. 100, pp. 560-564, (Mar. 2004).
- Di Lazzaro, V. et al., "Theta-burst repetitive transcranial magnetic stimulation suppresses specific excitatory circuits in the human motor cortex," *Physiology in Press*; published online on Apr. 21, 2005 as 10.1113/jphysio.2005.087288.
- Ding, Yumin et al., "Neural Plasticity After Spinal Cord Injury," *Current Pharmaceutical Design*, vol. 11, No. 11, pp. 1441-1450, Abstract Only -1 page (Apr. 2005).

- Duncan, Pamela W. et al., "Defining post-stroke recovery: implications for design and interpretation of drug trials," *Neuropharmacology* vol. 39, pp. 835-841 (2000).
- Feys et al., "Value of somatosensory and motor evoked potentials in predicting arm recovery after a stroke," (Oct. 1999).
- Franzini et al., "Reversal of thalamic hand syndrome by long-term motor cortex stimulation," *Journal of Neurosurgery* 93:873-875 (2000).
- Fregni, Felipe et al., "Anodal Transcranial Direct Current Stimulation of Prefrontal Cortex Enhances Working Memory," *Experimental Brain Research*, vol. 166, No. 1, pp. 23-30 (Sep. 2005).
- Gladstone et al., "Enhancing Recovery after Stroke with Noradrenergic Pharmacotherapy: A New Frontier?," *Can J. Neurol. Sci.*, vol. 27, No. 2 (May 2000).
- Gordon et al., "Parameters for direct cortical electrical stimulation in the human: histopathologic confirmation," *Electroencephalography and clinical Neurophysiology*, vol. 75, pp. 371-377 (1990).
- Hagemann, Georg et al., "Increased Long-Term Potentiation in the Surround of Experimentally Induced Focal Cortical Infarction," *Annals of Neurology*, vol. 44, No. 2, pp. 255-258 (Aug. 1998).
- Hayakawa, Toshiji et al., "Changes in Cerebral Oxygenation and Hemodynamics During Obstructive Sleep Apneas," *Chest*, vol. 109, pp. 916-921 (1996).
- Hodge, Jr., C.J. and Boakye, M., "Biological Plasticity: The Future of Science in Neurosurgery," *Neurosurgery*, vol. 48, No. 1 (Jan. 2001).
- Hoshi, Yoko et al., "Detection of dynamic changes in cerebral oxygenation coupled to neuronal function during mental work in a man," *Neuroscience Letters*, vol. 150, pp. 5-8 (1993).
- Hoshino et al., "Application of multichannel near-infrared spectroscopic topography to physiological monitoring of the cortex during cortical mapping: technical case report," *Surgical Neurology*, vol. 64, pp. 272-275 (2005).
- Huang, Ying-Zu et al., "Theta Burst Stimulation of the Human Motor Cortex," *Neuron*, vol. 45, pp. 201-206 (Jan. 20, 2005).
- Hummel, Friedhelm et al., "Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke," *Brain Advance Access*, Jan. 5, 2005, pp. 1-10, Brain.
- Kauhanen et al., "Domains and Determinants of Quality of Life After Stroke Caused by Brain Infarction," *Arch. Phys. Med. Rehabil.*, vol. 81, pp. 1541-1546 (Dec. 2000).
- Kilgard, Michael et al., "Cortical Map Reorganization Enabled by Nucleus Basalis Activity," *Science*, vol. 279 pp. 1714-1717 (Mar. 13, 1998).
- Kopell et al., "The Continuing Evolution of Psychiatric Neurosurgery," *CNS Spectrums*, vol. 5, No. 10, pp. 20-31 (Oct. 2000).
- L-DOPA dyskinesias. *BioChemistry of PD*. [Retrieved on Dec. 22, 2005]. Retrieved from the internet <URL <http://www.mayo.edu/fdp/pd-info/dyskinesias.htm>>.
- Lang, Nicolas et al., "Preconditioning with Transcranial Direct Current Stimulation Sensitizes the Motor Cortex to Rapid-Rate Transcranial Magnetic Stimulation and Controls the Direction of After-Effects," *Biol Psychiatry* 2004;56:634-639, 2004 Society of Biological Psychiatry.
- Larson, John et al., "Reversal of LTP by theta frequency stimulation," *Brain Research*, 600: pp. 97-102 (1993).
- Lazar, M. et al., "White Matter Tractography Using Diffusion Tensor Deflection," *Human Brain Mapping*, 18:306-321, (2003).
- Levy et al., "Functional MRI Evidence of Cortical Reorganization in Upper-Limb Stroke Hemiplegia Treated with Constraint-Induced Movement Therapy," *American Journal of Physical Medicine & Rehabilitation*, vol. 80, No. 1, pp. 4-7 (2001).
- Liepert et al., "Treatment-Induced Cortical Reorganization After Stroke in Humans," *Stroke*, 31:1210-1216 (2000).
- Malenka, R.C. and Nicoll, R.A., "Long-Term Potentiation and Depression: A Decade of Progress?," *Neuroscience*, vol. 285, No. 5435, Issue of Sep. 17, 1999, pp. 1870-1874.
- Mansur, C.G., et al., "A sham stimulation-controlled trial of rTMS of the unaffected hemisphere in stroke patients," *Neurology*, vol. 64, pp. 1802-1804 (2005).
- Martin et al., "Transcranial Magnetic Stimulation as a Complementary Treatment for Aphasia," *Semin Speech Language*, vol. 25, pp. 181-191 (2004) Abstract Only- 1 page.
- Martinez et al., "Motor hand recovery after stroke Prognostic yield of early transcranial magnetic stimulation," *Electromyography. Clin. Neurophysiology*, vol. 39, pp. 405-410 (1999).
- Netz et al., "Reorganization of motor output in the non-affected hemisphere after stroke," *Brain*, 120, pp. 1579-1586 (1997).
- Nitsche, M.A. and Paulus, W., "Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation," *The Journal of Physiology*, vol. 527.3, pp. 663-639 (2000).
- Nitsche, Michael A. et al., "Level of action of cathodal DC polarisation induced inhibition of the human motor cortex," *Dec. 2, 2002, Clinical Neurophysiology* 114 (2003) 600-604.
- Nitsche, Michael A., et al., "Facilitation of implicit Motor Learning by Weak Transcranial Direct Current Stimulation of the Primary Motor Cortex in the Human," *Journal of Cognitive Neuroscience* 15:4, pp. 619-626, 2003 Massachusetts Institute of Technology.
- Oliveri et al., "Paired transcranial magnetic stimulation protocols reveal a pattern of inhibition and facilitation in the human parietal cortex," *The Journal of Physiology*, 529.2, pp. 461-468 (2000).
- Panchanathan, Sethuraman et al., "Rehabilitation of patients with hemispatial neglect using visual-haptic feedback in Virtual reality environment," [Retrieved on Dec. 22, 2005]. Retrieved from the internet <URL <http://www.public.asu.edu/~tmcdani/publications.htm>>.
- Pascual-Leone et al., "Study and Modulation of Human Cortical Excitability With Transcranial Magnetic Stimulation," *Journal of Clinical Neurophysiology*, vol. 15, No. 4 (1998).
- Pascual-Leone et al., "Transcranial magnetic stimulation and neuroplasticity," *Neurophysiologia* 37, pp. 207-217 (1999).
- Paulus, W., "Transcranial direct current stimulation (tDCS)," *Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation (Supplements to Clinical Neurophysiology; vol. 56)*, pp. 249-254, 2003 Elsevier Science, B.V.
- Paulus, Walter, "Toward Establishing a Therapeutic Window for rTMS by Theta Burst Stimulation," *Neuron*, vol. 45, pp. 181-183 (Jan. 20, 2005).
- Penn, Michael, "Stemming Parkinson's," *On Wisconsin Alumni Magazine*, Summer 2003, [Retrieved on Dec. 22, 2005]. Retrieved from the internet <URL http://www.uwalumni.com/onwisconsin/2003_summer/research.html>.
- Rezaei, "Neurostimulation," *Neurological Research*, vol. 22, No. 3 pp. 235-273 (Apr. 2000).
- Rossi et al., "Effects of Repetitive Transcranial Magnetic Stimulation on Movement-related Cortical Activity in Humans," *Cerebral Cortex*, vol. 10, No. 8, pp. 802-808 (Aug. 2000).
- Roux et al., "Chronic Motor Cortex Stimulation for Phantom Limb Pain: A Functional Magnetic Resonance Imaging Study: Technical Cast Report," *Neurosurgery*, vol. 49, No. 3 (Mar. 2001).
- Saitou et al., "Cerebral Blood Volume and Oxygenation Among Poststroke Hemiplegic Patients: Effects of 13 Rehabilitation Tasks Measured by Near-Infrared Spectroscopy," *Arch. Phys. Med. Rehabil.*, vol. 81 pp. 1348-1356 (Oct. 2000).
- Sandkuhler, "Learning and memory in pain pathways," *Pain* 88, pp. 113-118 (2000).
- Sanes, "The Relation between Human Brain Activity and Hand Movements," *NeuroImage* 11, pp. 370-374 (2000).
- Sanes, J. and Donoghue, J.P., "Plasticity and Primary Motor Cortex," *Annual Review of Neuroscience* 23:393-415 (2000).
- Schaefer, Pamela W. et al., "Assessing Tissue Viability with MR Diffusion and Perfusion Imaging," *AJNR*, 24: pp. 436-443 (Mar. 2003).
- Schiene, Klaus et al., "Neuronal Hyperexcitability and Reduction of GABA-Receptor Expression in the Surround of Cerebral Photothrombosis," *Journal of Cerebral Blood Flow and Metabolism*, vol. 16, No. 5, pp. 906-914 (1996).
- Schiff et al., "A neuromodulation strategy for rational therapy of complex brain injury states," *Neurological Research*, vol. 22 pp. 267-272 (Apr. 2000).
- SCIRun. Scientific Computing and Imaging Institute, 2 pages. [Retrieved on Jul. 24, 2005]. Retrieved from the internet: <URL: <http://software.sci.utah.edu/scirun.html>>.

- Shimizu et al., "Therapeutic efficacy of transcranial magnetic stimulation for hereditary spinocerebellar degeneration," *Tohoku Journal of Experimental Medicine*, 189(3):203-11 (Nov. 1999).
- Siebner et al., "Lasting cortical activation after repetitive TMS of the motor cortex," *Neurology* 54, pp. 956-963 (Feb. 2000).
- Stefan et al., "Introduction of plasticity in the human motor cortex by paired associative stimulation," *Brian*, vol. 123, No. 3, pp. 575-584 (Mar. 2000).
- Strangman, Gary et al., "Non-Invasive Neuroimaging Using Near-Infrared Light," *Biological Psychiatry*, vol. 52, pp. 679-693 (2002).
- Strangman, Gary et al., "A Quantitative Comparison of Simultaneous BOLD fMRI and NIRS Recordings during Functional Brain Activation," *NeuroImage*, vol. 17, pp. 719-731 (2002).
- Strangman, Gary et al., "Factors affecting the accuracy of near-infrared spectroscopy concentration calculations for focal changes in oxygenation parameters," *NeuroImage*, vol. 18, pp. 865-879 (2003).
- Strens, Lucy et al., "The ipsilateral Human Motor Cortex Can Functionally Compensate for Acute Contralateral Motor Cortex Dysfunction," *Current Biology*, vol. 13, pp. 1201-1205 (Jul. 15, 2003).
- Taga, Gentaro et al., "Brain imaging in awake infants by near-infrared optical topography," *PNAS*, vol. 100, No. 19, pp. 10722-10727 (Sep. 16, 2003).
- The GES 250 for Dense-Array EEG Research. Electrical Geodesics, Inc., 3 pages. [Retrieved on Aug. 25, 2005]. Retrieved from the internet: <URL: http://www.egi.com/ges250r_n.html>.
- The INVOS Cerebral Oximeter. Somanetics, 1 page [Retrieved on Dec. 22, 2005]. Retrieved from the internet <URL <http://www.somanetics.net/invos.htm>>.
- Theoret, Hugo et al., "Exploring Paradoxical Functional Facilitation with TMS," *Supplements to Clinical Neurophysiology*, vol. 56, pp. 211-219 (2003).
- Thomas, Carmen et al., "Do Children with aggressive behavior have temporal lobe changes?" *Alasbimn Journal*, Year 5, No. 19, 8 pages (Jan. 2003).
- Torunov, Vlad et al., "Near-infrared study of fluctuations in cerebral hemodynamics during rest and motor stimulation: Temporal analysis and spatial mapping," *Medical Physics*, vol. 27, No. 4, pp. 801-815 (Apr. 2000).
- Tractography. Absolute Astronomy Reference, 2 pages. [Retrieved on Jul. 24, 2005]. Retrieved from the internet: <URL: <http://www.absoluteastronomy.com/encyclopedia/T/Tr/Tractography.htm>>.
- Tsubokawa, T., "Chronic Motor Cortex Stimulation in Patients with Thalamic Pain," *J. Neurosurg* 78:393-401, (Mar. 1993).
- Tuch, D. et al., "Conductivity Tensor Mapping of the Human Brain Using Diffusion Tensor MRI," *Neurobiology*, vol. 98 No. 20, pp. 11697-11701 (Sep. 25, 2001).
- Turton et al., "Contralateral and ipsilateral EMG responses to transcranial magnetic stimulation during recovery of arm and hand function after stroke," *Electroencephalography and Clinical Neurophysiology* 101 pp. 316-328 (1996).
- Turton, A. and Lemon, R.N., "The contribution of fast corticospinal input to the voluntary activation of proximal muscles in normal subjects and in stroke patients," *Exp. Brain Res.*, vol. 129, pp. 559-572 (1999).
- Van Der Lee et al., "The Intra- and Interrater Reliability of the Action Research Arm Test: A Practical Test of Upper Extremity Function in Patients With Stroke," *Arch. Phys. Med. Rehabil.*, vol. 82 pp. 14-19 (Jan. 2001).
- Walker-Batson et al., "Amphetamine Paired With Physical Therapy Accelerates Motor Recovery After Stroke," *Stroke*, vol. 26, No. 12, pp. 2254-2259 (1995).
- Weinand, Martin E. et al., "Cerebral blood flow and temporal lobe epileptogenicity," [Retrieved on Dec. 22, 2005]. Retrieved from the internet: <URL <http://www.aans.org/education/journal/neurosurgical/nov96/1-5-3.asp>>.
- Ziennann et al., "Modulation of Plasticity in Human Motor Cortex after Forearm Ischemic Nerve Block," *The Journal of Neuroscience* 18(3):1115-1123 (Feb. 1998).
- Bury, Scott et al., "The Effects of Behavioral Demand on Motor Cortical and Cerebellar Structural Plasticity After Brain Injury in Adult Rats," [Retrieved on Mar. 1, 2003]. Retrieved from the internet: <URL: <http://www.mcmaster.ca/inabis98/schallert/bury0827/two.html#introduction>>.
- Keyvani, Kathy et al., "Suppression of proteasome C2 contralateral to ischemic lesions in rat brain," *Brain Research*, vol. 858, pp.: 386-392, 2000.
- Nudo, Randolph J., et al., "Recovery after damage to motor cortical areas," *Current Opinion in Neurobiology*, vol. 9, Issue 6, pp.: 740-747, Dec. 1, 1999.
- Cao, Yue et al., "Cortical Language Activation in Stroke Patients Recovering From Aphasia With Functional MRI," *Stroke*, vol. 30, pp. 2331-2340, Nov. 1999.
- Bluestone, Avraham Y. et al., "Three-dimensional optical tomography of hemodynamics in the human head," *Optics Express*, vol. 9, No. 6, pp.: 272-286 (Sep. 10, 2001).
- How Imagent™ Works. ISS Inc., 1 page [Retrieved on Oct. 14, 2005]. Retrieved from the internet: <URL http://www.iss.com/Products/imagent_fmri.html>.
- Imagent™ Functional Brain Imaging System. ISS, Inc., 2 pages [Retrieved on Oct. 14, 2005]. Retrieved from the internet: <URL <http://www.iss.com/Products/imagent.html>>.
- Imagent™ functional Near Infrared Imaging System (fNIRS) Brain Imaging Using Infrared Photons. ISS Inc., 8 pages [Retrieved on Oct. 14, 2005]. Retrieved from the internet: <URL <http://www.iss.com/products/imagent/Imagent.pdf>>.
- Janicek, Milos J. et al., "Dynamic Infrared Imaging of Newly Diagnosed Malignant Lymphoma Compared with Gallium-67 and Fluorine-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography," *Technology in Cancer Research and Treatment*, vol. 2, No. 6, pp.: 571-577 (Dec. 2003).
- Tang, Cha-Min et al., "Optical Coherence Tomography of the Human Basal Ganglion," *Deep Brain Stimulation Consortium Meeting Program Book*, Sep. 29-30, 2003, Washington DC.
- Timmermann, Lars et al., "The cerebral oscillatory network of parkinsonian resting tremor," *Brain*, vol. 126, pp.: 199-212, (2003).
- Yokoh, Arika et al., "Intermittent versus continuous brain retraction," *Journal of Neurosurgery*, vol. 58, pp.: 918-923 (Jun. 1983).

* cited by examiner




FIG. 1




FIG. 2

FIG. 3





FIG. 4

300



FIG. 5

FIG. 6

1

SYSTEMS AND METHODS FOR ENHANCING OR OPTIMIZING NEURAL STIMULATION THERAPY FOR TREATING SYMPTOMS OF PARKINSON'S DISEASE AND/OR OTHER MOVEMENT DISORDERS

CROSS-REFERENCE TO RELATED APPLICATION(S)

The present disclosure incorporates by reference U.S. application Ser. No. 09/978,134 entitled "Systems and Methods for Automatically Optimizing Stimulus Parameters and Electrode Configurations for Neuro-Stimulators," filed on Oct. 15, 2002; and U.S. Application No. 60/432,073 entitled "System and Method for Treating Parkinson's Disease and Other Movement Disorders," filed on Dec. 9, 2002 (Perkins Coie Docket No. 33734.8040US00- Express Mail No. EV139295255US).

TECHNICAL FIELD

The present disclosure relates generally to systems and methods for treating symptoms of Parkinson's Disease and/or other movement disorders. More particularly, the present disclosure describes a system and method for enhancing or optimizing the effectiveness of neural stimulation in treating the symptoms of movement disorders such as Parkinson's Disease.

BACKGROUND

A wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain. For example, various physical or cognitive functions are directed or affected by neural activity within the sensory or motor cortices. Across most individuals, particular areas of the brain appear to have distinct functions. In the majority of people, for example, the areas of the occipital lobes relate to vision; the regions of the left interior frontal lobes relate to language; portions of the cerebral cortex appear to be consistently involved with conscious awareness, memory, and intellect; and particular regions of the cerebral cortex as well as the basal ganglia, the thalamus, and the motor cortex cooperatively interact to facilitate motor function control.

Many problems or abnormalities with body functions can be caused by damage, disease, and/or disorders in the brain. For example, Parkinson's Disease (PD) is related to the degeneration or death of dopamine producing neurons in the substantia nigra region of the basal ganglia in the brain. Dopamine is neurotransmitter that transmits signals between areas of the brain. As the neurons in the substantia nigra deteriorate, the reduction in dopamine causes abnormal neural activity that results in a chronic, progressive deterioration of motor function control. Conservative estimates indicate that PD may affect more than one million individuals in the United States alone.

PD patients typically exhibit one or more of four primary symptoms. One primary symptom is a tremor in an extremity (e.g., a hand) that occurs while the extremity is at rest. Other primary symptoms include a generalized slowness of movement (bradykinesia); increased muscle rigidity or stiffness (rigidity); and gait or balance problems (postural dysfunction). In addition to or in lieu of these primary symptoms, PD patients may exhibit secondary symptoms including: difficulty initiating or resuming movements; loss of fine motor skills; lack of arm swing on the affected side

2

of the body while walking; foot drag on the affected side of the body; decreased facial expression; voice and/or speech changes; cognitive disorders; feelings of depression or anxiety; and/or other symptoms.

Effectively treating PD or other movement disorders related to neurological conditions can be very difficult. Current treatments for PD symptoms include drugs, ablative surgical intervention, and/or neural stimulation. Drug treatments or therapies may involve, for example, the administration of a dopamine precursor that is converted to dopamine within the central nervous system (i.e., Levodopa (L-dopa)). Other types of drug therapies are also available. Unfortunately, drug therapies frequently become less effective or ineffective over time for an undesirably large patient population. A PD patient may require multiple drugs in combination to extend the time period of efficacy of drug therapies. Drug treatments additionally have a significant likelihood of inducing undesirable physical side effects; motor function complications such as uncontrollable involuntary movements (dyskinesias) are a particularly common side effect. Furthermore, drug treatments may induce undesirable cognitive side effects such as confusion and/or hallucinations.

Ablative surgical intervention for PD typically involves the destruction of one or more neural structures within the basal ganglia or thalamus that have become overactive because of the lack of dopamine. Unfortunately, such neural structures reside deep within the brain, and hence ablative surgical intervention is a very time consuming and highly invasive procedure. Potential complications associated with the procedure include risk of hemorrhage, stroke, and/or paralysis. Moreover, because PD is a progressive disease, multiple deep brain surgeries may be required as symptoms progressively worsen over time. Although ablative surgical intervention may improve a PD patient's motor function, it is not likely to completely restore normal motor function. Furthermore, since ablative surgical intervention permanently destroys neural tissue, the effects of such intervention cannot be readily adjusted or "fine tuned" over time.

Neural stimulation treatments have shown promising results for reducing some of the symptoms associated with PD. Neural activity is governed by electrical impulses or "action potentials" generated in and propagated by neurons. While in a quiescent state, a neuron is negatively polarized and exhibits a resting membrane potential that is typically between -70 and -60 mV. Through chemical connections known as synapses, any given neuron receives excitatory and inhibitory input signals or stimuli from other neurons. A neuron integrates the excitatory and inhibitory input signals it receives, and generates or fires a series of action potentials in the event that the integration exceeds a threshold potential. A neural firing threshold, for example, may be approximately -55 mV. Action potentials propagate to the neuron's synapses and are then conveyed to other synaptically connected neurons.

Neural activity in the brain can be influenced by neural stimulation, which involves the application of electrical and/or magnetic stimuli to one or more target neural populations within a patient using a waveform generator or other type of device. Various neural functions can thus be promoted or disrupted by applying an electrical current to one or more regions of the brain. As a result, researchers have attempted to treat certain neurological conditions, including PD, using electrical or magnetic stimulation signals to control or affect brain functions.

Deep Brain Stimulation (DBS) is a stimulation therapy that has been used as an alternative to drug treatments and

3

ablative surgical therapies. In DBS, one or more electrodes are surgically implanted into the brain proximate to deep brain or subcortical neural structures. For treating PD or other movement disorders, the electrodes are positioned in or proximate to the ventrointermediate nucleus of the thalamus; basal ganglia structures such as the globus pallidus internalis (GPi); or the Subthalamic Nucleus (STN). The location of the stimulation site for the electrodes depends upon the symptoms that a patient exhibits and the severity of the symptoms.

In a typical DBS system, a pulse generator delivers a continuous or essentially continuous electrical stimulation signal having a pulse repetition frequency of approximately 100 Hz to each of two deep brain electrodes. The electrodes are bilaterally positioned on the left and right sides of the brain relative to particular neural structures such as those indicated above. U.S. Pat. No. 5,883,709 discloses one conventional DBS system for treating movement disorders.

Although DBS therapies may significantly reduce one or more PD symptoms, particularly when combined with drug treatments, they are highly invasive procedures. In general, configuring a DBS system to properly function within a patient requires two time consuming, highly invasive surgical procedures for implanting the DBS electrodes. Each such surgical procedure has essentially the same risks as those described above for ablative surgical intervention. Moreover, DBS may not provide relief from some movement disorders.

Motor Cortex Stimulation (MCS) is another type of brain stimulation treatment that has been proposed for treating movement disorders. MCS involves the application of stimulation signals to the motor cortex of a patient. One MCS system includes a pulse generator connected to a strip electrode that is surgically implanted over a portion of only the motor cortex (precentral gyrus). The use of MCS to treat PD symptoms is described in Canavero, Sergro, *Extradural Motor Cortex Stimulation for Advanced Parkinson's Disease: Case Report*, Movement Disorders (Vol. 15, No. 1, 2000).

Because MCS involves the application of stimulation signals to surface regions of the brain rather than deep neural structures, electrode implantation procedures for MCS are significantly less invasive and time consuming than those for DBS. As a result, MCS may be a safer and simpler alternative to DBS for treating PD symptoms. Present MCS techniques, however, fail to address or adequately consider a variety of factors that may enhance or optimize the extent to which a patient experiences short term and/or long term relief from PD symptoms.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic illustration of a neural stimulation system for treating symptoms of Parkinson's Disease and/or other neurological disorders according to an embodiment of the invention.

FIG. 2 is a graph illustrating several stimulation parameters that may define, describe, or characterize stimulation signals.

FIG. 3 is a flowchart illustrating various methods for refining, enhancing, or optimizing neural stimulation therapy for treating symptoms of Parkinson's Disease and/or other movement disorders according to an embodiment of the invention.

FIG. 4 is a flowchart illustrating various methods for establishing, adjusting, or adapting a test protocol according to an embodiment of the invention.

4

FIG. 5 is a flowchart illustrating various methods for determining neural stimulation parameters according to an embodiment of the invention.

FIG. 6 is a flowchart illustrating various methods for modifying, adjusting, or adapting neural stimulation therapy in view of a likelihood or possibility of a lasting or long term neuroplastic change occurring within a patient over time.

DETAILED DESCRIPTION

The following disclosure describes neural stimulation systems and methods for enhancing or optimizing the extent to which a patient may experience relief from symptoms associated with Parkinson's Disease (PD), other movement or motor disorders, and/or various neurological disorders that may have multiple types of symptoms. Such symptoms may include, for example, tremor, rigidity, bradykinesia, postural dysfunction, spasticity, speech deficits, visual disturbances, olfactory deficits, cognitive deficits, memory deficits, emotional or psychiatric disturbances, paresis, pain and/or other symptoms.

Different symptoms may respond to neural stimulation in different manners, and/or across different time scales. For example, neural stimulation optimized to beneficially affect tremor and/or rigidity to a significant degree may provide less significant or minimal benefit relative to other symptoms such as postural dysfunction. Additionally, neural stimulation that has a nearly immediate or reasonably rapid effect upon tremor and/or rigidity may have a significantly or greatly delayed effect upon other symptoms such as bradykinesia. Systems and/or methods described herein may facilitate enhancement or optimization of neural stimulation therapy for treating multiple patient symptoms that may exhibit different treatment response characteristics and/or different response timeframes.

Neural stimulation may facilitate or effectuate neuroplastic changes within a patient's brain, for example, in a manner described in U.S. application Ser. No. 09/802,808, which is incorporated herein by reference. Neuroplastic changes can include adaptive structural changes or reorganizations in particular brain regions, which may result in enhancement or restoration of one or more functional abilities (i.e., physical, sensory, and/or cognitive functions) associated with such brain regions, possibly on a long term or lasting basis. Application of neural stimulation to a patient in accordance with the principles described herein may increase the likelihood that neuroplastic changes can occur to facilitate at least partial recovery of diminished or lost functionality associated with or giving rise to one or more patient symptoms. Such functional recovery may itself reduce the extent to which the patient requires neural stimulation and/or other therapy on an ongoing basis.

FIG. 1 is a schematic illustration of a neural stimulation system 100 for treating symptoms of PD and/or other disorders according to an embodiment of the invention. In one embodiment, the neural stimulation system 100 comprises a pulse generator 110a configured to deliver stimulation signals to a patient 190 using a set of electrodes 140. The pulse generator 110a may be coupled to the set of electrodes 140 by one or more leads 112. The pulse generator 110a may further be configured for wireless and/or wire-based communication with a programming unit 160. Depending upon embodiment details, the system 100 may further include one or more patient monitoring units 180 configured to detect, monitor, indicate, measure, and/or assess the severity of particular types of patient symptoms.

5

The set of electrodes **140** may include one or more cortical electrodes **142** configured to provide, deliver, and/or apply stimulation signals to particular cortical regions of the patient's brain **192** and/or neural populations synaptically connected and/or proximate thereto. A cortical electrode **142** may include one or more electrically conductive contacts **144** carried by a substrate **146** in a manner understood by those skilled in the art. The set of electrodes **140** may alternatively or additionally include one or more penetrating, depth, and/or deep brain electrodes. The set of electrodes **140** may further include or provide one or more stimulation signal return electrodes (i.e., electrodes that provide a current return path) that may be positioned relative to a variety of locations within and/or upon the patient's body.

The characteristics and/or placement of the set of electrodes **140** may depend upon the nature of patient's underlying disorder(s) and/or the type and/or severity of symptoms that the patient **190** experiences or exhibits. In one embodiment, one or more portions of the set of electrodes **140** may be surgically implanted to deliver stimulation signals to target neural populations within the patient's brain in a manner described in U.S. Application No. 60/432,073, entitled "System and Method for Treating Parkinson's Disease and Other Movement Disorders," filed on Dec. 9, 2002 (Perkins Coie Docket No. 33734.8040US00).

The pulse generator **110a** may comprise hardware and/or software for generating and outputting stimulation signals to the set of electrodes **140** in accordance with internal instruction sequences and/or in response to control signals, commands, instructions, and/or other information received from the programming unit **160**. The pulse generator **110a** may include a power supply, a pulse unit, a control unit, a programmable computer medium, and a communication unit. The power supply may comprise a battery or other type of power storage device. The pulse unit may comprise circuitry for generating pulse sequences that may be defined or characterized in accordance with various stimulation signal parameters, which are further described below with reference to FIG. 2. The control unit may comprise hardware and/or software configured to direct or manage the local operation of the pulse generator **110a**. The communication unit may comprise a user interface that facilitates communication with devices external to the pulse generator **110a**, for example, through telemetric signal transfer. The programmable computer medium may comprise hardware and/or memory resident software. The programmable computer medium may store operational mode information and/or program instruction sequences that may be selected and/or specified in accordance with information received from the programming unit **160**. The pulse generator **110a** may be configured to deliver stimulation signals to particular electrodes **142** and/or specific electrical contacts **144** within the set of electrodes **140** on a selective basis at any given time, in a manner identical, essentially identical, or analogous to that described in U.S. application Ser. No. 09/978,134.

Each element of the pulse generator **110a** may be incorporated or embedded into a surgically implantable case or housing. Depending upon embodiment details, the pulse generator **110a** may be surgically implanted into the patient **190** in a subclavicular location. Alternatively, a pulse generator **110b** may be surgically implanted above the patient's neck, for example, in a skull location posterior to the patient's ear and/or proximate to an electrode implantation site. A surgically formed tunnel or path may route the set of leads **112** that couple the pulse generator **110a**, **110b** to the set of electrodes **140**, in a manner understood by those

6

skilled in the art. Additionally, one or more electrically conductive portions of the pulse generator's case or housing may serve as a return electrode for electrical current.

The programming unit **160** may comprise a device configured to communicate control signals, commands, instructions, and/or other information to the pulse generator **110a**. The programming unit **160** may additionally be configured to receive information from the pulse generator **110a**. Communication between the programming unit **160** and the pulse generator **110a** may facilitate or effectuate specification, selection, and/or identification of operational modes, instruction sequences, and/or procedures for treating symptoms of PD and/or other neurological disorders in accordance with the present invention, as described in detail below with reference to FIGS. 3 through 6.

In one embodiment, the programming unit **160** includes a processing unit **162**, a programmable computer medium **164**, and a communication unit **166**. The programmable computer medium **164** may store an operating system, program instructions, and/or data, and may comprise various types of hardware and memory resident software, including volatile and/or nonvolatile memory as well as one or more data storage devices. The communication unit **166** may include a wire-based and/or wireless telemetry interface **170** that employs magnetic, radio frequency (RF), and/or optical signaling techniques to communicate with the pulse generator **110a**. The communication unit **166** may additionally or alternatively include one or more wire-based and/or wireless interfaces that facilitate communication with other devices such as a computer.

A patient monitoring unit **180** may comprise essentially any type of device, subsystem, and/or system configured to detect, monitor, indicate, measure, and/or assess the severity of one or more types of patient symptoms associated with PD and/or other neurological disorders. For example, a patient monitoring unit **180** may comprise a motion detection system configured to detect patient movement associated with tremor. A motion detection system may include light emitting and/or detecting devices and/or accelerometers coupled to particular patient extremities. As another example, a patient monitoring unit **180** may comprise an Electromyography (EMG) system that includes a set of surface or depth electrodes positioned relative to particular muscle groups for detecting electrical signals corresponding to muscle fiber innervation. As another example, a patient monitoring unit **180** may comprise an Electroencephalography (EEG) system. As yet another example, a patient monitoring unit **180** may comprise a neural imaging system. As a final example, a patient monitoring unit **180** may comprise one or more electrodes and/or probes (e.g., cerebral bloodflow monitors) positioned upon, proximate, and/or within given target neural populations, and associated hardware and/or software for detecting, presenting, and/or analyzing signals received therefrom.

As previously indicated, the pulse generator **110a** generates and outputs stimulation signals. In the context of the present invention, stimulation signals may comprise electromagnetic pulse sequences. Any given pulse sequence may comprise at least one, and possibly multiple, pulse trains, which may be separated by quiescent intervals. FIG. 2 is a graph illustrating several stimulation parameters that may define, describe, or characterize a pulse train. A stimulus start time t_0 defines an initial point at which a pulse train is applied to one or more elements within the set of electrodes **140**. In one embodiment, the pulse train may be a biphasic waveform comprising a series of biphasic pulses, and which may be defined, characterized, or described by parameters

including a pulse width t_1 for a first pulse phase; a pulse width t_2 for a second pulse phase; and a pulse width t_3 for one or more biphasic pulses. The parameters can also include a pulse repetition rate $1/t_4$ corresponding to a pulse repetition frequency; a pulse duty cycle equal to t_3 divided by t_4 ; a pulse burst time t_5 that defines a number of pulses in a pulse train; and/or a pulse train repetition rate t_6 . Other parameters include a peak current intensity or amplitude I_1 for a first pulse phase and a peak current intensity I_2 for a second pulse phase.

In various embodiments, the pulse width of successive pulses and/or successive pulse phases may vary, such that the pulse repetition frequency within a pulse train and/or a pulse sequence is a function of time. A pulse train having a frequency that varies in time may give rise to a "chirped" frequency profile. Additionally or alternatively, the pulse intensity or amplitude may decay during the first and/or second pulse phases, and the extent of such decay may differ across successive or subsequent pulse phases. Those skilled in the art will understand that a pulse may be a charge-balanced waveform, and that in an alternate embodiment, pulses can be monophasic or polyphasic. Additional stimulation parameters may specify manners in which pulse trains are applied to selected configurations of elements within the set of electrodes **140**, such as particular electrodes **142** and/or contacts **144**, at any given time.

As defined herein, a test protocol may define or specify neural stimulation parameters associated with one or more pulse sequences to be applied to a patient **190** across or within a given test period duration that may include one or more neural stimulation delivery periods and possibly one or more quiescent periods during which the patient **190** receives no neural stimulation. A test protocol may further define or specify a spatial and/or temporal distribution of elements within the set of electrodes **140** to which neural stimulation may be applied during one or more portions of the test period; and corresponding signal polarities corresponding to particular elements within the set of electrodes **140** relative to one or more portions of the test period. Neural stimulation delivered in accordance with a test protocol comprises a test therapy.

FIG. **3** is a flowchart illustrating various methods for refining, enhancing, or optimizing neural stimulation therapy for treating symptoms of PD and/or other neurological disorders according to an embodiment of the invention. In one embodiment, a method **200** includes an identification procedure **202** that involves identification of one or more patient symptoms to which neural stimulation therapy, possibly in conjunction with one or more adjunctive therapies, may be directed. The method **200** may also include a symptom selection procedure **204** that involves selection or consideration of a first, a next, or an additional subset of patient symptoms to which neural stimulation therapy may be directed. The symptom selection procedure **204** may facilitate initial selection of symptoms expected to rapidly respond to neural stimulation, such as tremor and/or rigidity, followed by selection of other symptoms such as bradykinesia that may respond more slowly.

The method **200** may further include a test protocol management procedure **206** that involves establishing, adjusting, and/or adapting a test protocol that specifies or defines a test therapy intended to be applied to the patient **190** for a given test period. The test protocol may specify or define neural stimulation parameters corresponding to the test therapy, and may also specify parameters corresponding to one or more adjunctive therapies such as drug therapies.

The method **200** may additionally include a test delivery procedure **208** that involves application or delivery of the test therapy to the patient **190** in accordance with the test protocol; and an observation procedure **210** that involves observation, monitoring, and/or measuring of patient symptoms at one or more times in association with and/or following the delivery procedure **208**. The observation procedure **210** may involve one or more patient monitoring units **180**, and/or direct human observation of the patient **190**.

The method **200** may further include an evaluation procedure **212** involving determination of an extent to which one or more patient symptoms currently under consideration have improved or changed as a result of the most recently applied test therapy. In a manner analogous to that for the observation procedure **210**, the evaluation procedure **212** may involve one or more patient monitoring units **180** and/or direct human evaluation of the patient **190**. In the event that further improvement of symptoms currently under consideration is necessary, likely, or possible, the method **200** may return to the test protocol management procedure **206**. Alternatively, in the event that additional patient symptoms require consideration, the method **200** may return to the symptom selection procedure **204**.

In addition to procedures directed toward refining, enhancing, or optimizing an extent to which one or more symptoms can be successfully or adequately treated by neural stimulation (possibly in conjunction with one or more adjunctive therapies), the method **200** may include an ongoing treatment delivery procedure **218** that involves application of an arrived-at ongoing therapy to the patient in accordance with an ongoing, essentially ongoing, or generally ongoing treatment protocol. The ongoing treatment protocol may correspond to or be based upon a previously considered test protocol, and may involve one or more adjunctive therapies. In particular, the ongoing treatment protocol may be identical or essentially identical to a recently considered test protocol, with the exception that an ongoing treatment duration corresponding to the ongoing treatment protocol may be significantly longer than that of the test period corresponding to such a test therapy.

The method **200** may also include a reevaluation procedure **220** that involves a one-time, occasional, or periodic reevaluation, adjustment, and/or adaptation of a most recent ongoing treatment protocol in view of potential or likely neuroplastic changes, variations in ongoing treatment effectiveness, and/or overall patient health or condition over time. Such reevaluation, adjustment, or adaptation may occur after a predetermined time interval, such as 1 month, several months, or 1 or more years following initiation of an ongoing treatment delivery procedure **218**. The reevaluation procedure **220** may be performed on a one-time or repeated basis based upon the judgment of a medical professional.

The reevaluation procedure **220** may itself involve one or more steps of the method **200**. Through a reevaluation procedure **220**, it may be determined that one or more patient symptoms may be better, successfully, or adequately treated or managed in accordance with a different pulse repetition frequency function; a lower peak intensity or amplitude; less frequent neural stimulation; a modified configuration of elements within the set of electrodes **140** and/or modified signal polarities applied thereto; lower dosage and/or less frequent drug therapy; and/or other variations in or modifications to the ongoing treatment protocol. As further described below with reference to FIG. **6**, a reevaluation procedure **220** that indicates that better, successful, or adequate treatment or management of one or more patient

symptoms may be achieved with less intense and/or less frequent neural stimulation may be indicative of compensatory, restorative, and/or rehabilitative neuroplastic change within the patient 190.

FIG. 4 is a flowchart illustrating various methods for establishing, adjusting, or adapting a test protocol according to an embodiment of the invention. Such methods may be used in the test protocol management procedure 206 of FIG. 3. In one embodiment, a method 300 includes an adjustment procedure 302 that involves adjustment, cessation, or interruption of patient therapies currently in progress as required. Such therapies may comprise neural stimulation and/or one or more adjunctive therapies such as a drug therapy. The method 300 may also include a waiting procedure 304 during which effects of recently adjusted, discontinued, or interrupted therapies are allowed to subside, stabilize, or “wash out.” The waiting procedure 304 may maximize or increase a likelihood that a previously applied therapy has a minimal or negligible effect upon an upcoming test therapy (i.e., no carry-over effects). The method 300 may further include an assessment procedure 306 that involves assessment, qualification, and/or quantification of the severity of one or more patient symptoms, possibly to establish a baseline or reference patient condition.

The method 300 may additionally include a duration establishment procedure 308 that involves determination or definition of a test period duration during which a test therapy may be applied to the patient 190. A test period duration may be short or relatively short, for example, approximately 1 or more minutes or hours, to facilitate efficient determination of the effectiveness of a test protocol upon acute or readily responsive patient symptoms. Alternatively, a test period duration may be relatively long, for example, approximately 1 or more days, weeks, or even months, to facilitate determination of the effectiveness of a test protocol upon patient symptoms having slower or prolonged treatment response characteristics. The method 300 may further include a first test protocol definition procedure 310 that involves determination, selection, and/or specification of neural stimulation parameters that comprise one or more portions of the test protocol. The method 300 may additionally include a second test protocol definition procedure 312 that involves determination or definition of a set of parameters corresponding to one or more adjunctive therapies that may form a portion of the test protocol. Such parameters may include, for example, a drug dosage and delivery schedule.

FIG. 5 is a flowchart illustrating various methods for determining neural stimulation parameters according to an embodiment of the invention. Such methods may be used in the first test protocol definition procedure 310 of FIG. 4. In one embodiment, a method 400 includes a delivery period selection procedure 402 that involves determination or selection of a first or next time interval within the current test period that neural stimulation may be delivered to the patient 190. The method 400 may further include a pulse sequence duration procedure 404 that involves selection and/or specification of one or more pulse sequence durations and/or quiescent intervals within and/or between pulse sequences for the neural stimulation delivery period currently under consideration. The method 400 may accommodate multiple pulse sequences, variable types of pulse train sequences, and/or quiescent intervals between pulse sequences to provide enhanced flexibility with respect to establishing test protocols that may be useful for efficiently treating symptoms of various disorders.

Relative to treating PD symptoms, stimulation that reduces the output activity of the globus pallidus internalis (GPi) can be highly beneficial. Deep Brain Stimulation (DBS) research has shown that stimulation delivered to the globus pallidus internalis (GPi) may significantly reduce GPi activity over a period that can last several seconds beyond the termination of such stimulation. For example, a continuous or essentially continuous pulse train lasting 3 seconds may result in reduced or significantly reduced GPi output activity that lasts approximately 1.5 seconds beyond termination of the 3 second pulse train. Delivering or applying neural stimulation to one or more target neural populations having synaptic projections into the GPi or associated neural circuitry such that pulse sequences or pulse trains are separated by one or more appropriate quiescent intervals may therefore maintain or sustain reduced GPi activity while eliminating the need to deliver continuous stimulation. Delivery of neural stimulation in such a manner advantageously reduces power consumption. Thus, a pulse sequence comprising periodic pulse trains lasting approximately 3 seconds separated by quiescent intervals lasting approximately 1.5 seconds may provide significant therapeutic benefit in a power efficient manner.

The method 400 may additionally include a waveform definition procedure 406 that involves selection and/or specification of a set of waveform parameters that define or describe each pulse sequence currently under consideration. Such waveform characteristics may include a pulse repetition frequency or frequency function, a pulse amplitude decay function, and/or other pulse sequence parameters. Depending upon embodiment details and/or current symptoms under consideration, the pulse repetition frequency may vary within any given pulse sequence, and/or from one pulse sequence to another. By accommodating such variation, the method may facilitate the definition of a test protocol or an arrived-at ongoing treatment protocol that includes multiple pulse repetition frequencies, where particular individual pulse frequencies or pulse frequency subsets may be directed toward maximizing or enhancing the effectiveness of neural stimulation in treating particular PD and/or movement disorder symptoms. As an illustrative example, if (a) a pulse repetition frequency of approximately 25 Hz appears optimal or nearly optimal for treating tremor, (b) a pulse repetition frequency of approximately 30 Hz appears optimal for treating rigidity, and (c) a pulse repetition frequency of approximately 15 Hz appears optimal for treating bradykinesia, then a test protocol or an ongoing treatment protocol may call for neural stimulation that periodically alternates between these pulse repetition frequencies in accordance with given neural stimulation delivery periods and possibly including one or more quiescent periods therebetween. Alternatively, the test protocol or the ongoing treatment protocol may call for neural stimulation that sweeps between 15 and 30 Hz in a continuous or nearly continuous manner.

In general, a test protocol may call for neural stimulation having one or more pulse repetition frequencies specified in accordance with a temporal and/or mathematical function that is based upon individual pulse repetition frequencies determined to be optimal or near-optimal for treating particular subsets of patient symptoms. Such a temporal and/or mathematical function may be based upon the nature and/or severity of such symptoms. For example, if the patient's baseline or reference state indicates that the patient experiences tremor in a significantly more severe manner than bradykinesia, a test protocol may call for neural stimulation in which an amount of time spent delivering stimulation

optimized or nearly optimized for treating tremor exceeds an amount of time spent delivering stimulation optimized or nearly optimized for treating bradykinesia. Additionally or alternatively, the test protocol may call for neural stimulation having a frequency function that is weighted or biased relative to individually determined frequencies corresponding to particular symptom subsets. Such a test protocol may call for neural stimulation that delivers, for example, a combined frequency of 27 Hz for treating both tremor and rigidity, as well as a pulse repetition frequency of 15 Hz for treating bradykinesia. Furthermore, a test protocol may call for neural stimulation having a pulse repetition frequency function that depends upon one or more treatment response times associated with particular symptoms, and/or one or more time intervals that relief from particular symptoms persists in the absence of neural stimulation.

The method **400** may further include an electrode element selection procedure **408** that involves identifying or defining a spatial and/or temporal distribution of electrodes **142** and/or contacts **144** to which neural stimulation may be directed during the delivery period under consideration. The electrode element selection procedure **408** may alternatively or additionally select or define signal polarities corresponding to particular electrodes **142** and/or contacts **144** relative to one or more portions of the test period. In the event that a current test period includes more than one delivery period, the method **400** may return to the delivery period selection procedure **402**.

The method **400** may also include a threshold determination procedure **412** that involves determination of a minimum or near minimum neural stimulation amplitude or intensity that evokes or induces a given type of patient response, reaction, behavior, and/or sensation. A neural stimulation threshold may be determined by successively applying higher amplitude neural stimulation signals to the patient **190** until an observable or detectable response occurs. Each threshold determination attempt may apply a limited duration neural stimulation signal to the patient **190**, for example, a pulse sequence lasting 0.5 seconds, 1 second, 3 seconds, or some other length of time. A waiting, quiescent, or washout period between successive threshold determination attempts, during which the patient **190** receives no neural stimulation, may ensure that each threshold determination attempt is independent or essentially independent of residual effects associated with previously applied signals. A quiescent period may span several seconds to one or more minutes, for example, approximately one minute. In one embodiment, the threshold determination procedure **412** involves determination of a motor, movement, or motion threshold through motion detection techniques and/or visual observation. In another embodiment, the threshold determination procedure **412** may involve determination of an EMG threshold and/or another type of neural stimulation threshold.

The method **400** may further include an amplitude determination procedure **414** that involves determination or selection of peak or average amplitudes or intensities corresponding to the set of pulse sequences defined or specified within the current test period based upon the results or outcome of the threshold determination procedure **412**. Depending upon embodiment details, a peak pulse sequence amplitude may be defined as a given percentage of a neural stimulation threshold, for example, 50% of a movement threshold or 70% of an EMG threshold. In some embodiments, different pulse sequences within a delivery period or test period may have different peak amplitudes.

FIG. **6** is a flowchart illustrating various methods for modifying, adjusting, or adapting neural stimulation therapy in view of a likelihood or possibility of a lasting or long term neuroplastic change occurring within a patient **190** over time. Such methods may involve the reevaluation procedure **220** and/or other procedures described above with in association with FIG. **3**. The propensity of a given neural population to undergo neuroplastic change may depend upon the application of an initial neural stimulation regimen to the neural population in a particular manner, such as a continuous, generally continuous, or frequent manner over a given or minimum amount of time. This may in turn facilitate or effectuate initiation and reinforcement of chemical and/or structural adaptations or changes in the neural population and/or neural circuitry associated therewith, thereby "priming" the neural population to accept and/or maintain long term or lasting neuroplastic change.

As an illustrative example, depending upon symptom type and severity, effective or generally effective treatment of PD or other movement disorder symptoms may initially require continuous, essentially continuous, or nearly continuous neural stimulation for a neuroplastic priming period of approximately one month. After such a neuroplastic priming period, however, effective treatment of one or more symptoms may require stimulation for a limited number of hours per day, such as during the patient's normal waking hours. Alternatively, effective treatment may require continuous stimulation for approximately 30 minutes, after which treatment may be interrupted for approximately 30 minutes, and so on. In another embodiment, the stimulation can be applied on a twenty four hour basis for an initial period and then on a reduced basis for a subsequent period. The stimulation, for example, can be applied all throughout each day for an initial period of approximately one month, and then it can be applied only during waking hours after the initial period. This is expected to provide sufficient results in many situations and conserve battery life.

One method **500** for modifying, adjusting, or adapting neural stimulation therapy in view of a likelihood or possibility of a lasting or long term neuroplastic change may include a first stimulation optimization or refinement procedure **502** that involves determination of a continuous neural stimulation protocol for treating one or more patient symptoms. The method **500** may further include a continuous stimulation procedure **504** that involves delivery or application of neural stimulation to the patient **190** in accordance with the continuous neural stimulation protocol for a predetermined time period, for example, one or more weeks or one or more months. The predetermined time period may correspond to an expected or likely neuroplastic priming period. The method **500** may additionally include a second stimulation optimization or refinement procedure **506** that involves determination of a noncontinuous and/or periodically interrupted neural stimulation protocol for treating patient symptoms under consideration. The method **500** may also include a noncontinuous or interrupted stimulation procedure that involves delivery of noncontinuous and/or interrupted neural stimulation to the patient **190** in accordance with the noncontinuous and/or interrupted neural stimulation protocol. The first and/or second stimulation optimization or refinement procedures **502**, **506** may include or encompass one or more procedures described above in association with FIG. **3**. Additionally, the second stimulation optimization or refinement procedure **506** may be repeated following application of noncontinuous or interrupted stimulation to the patient **190** for a given amount of time.

13

From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited 5 except as by the appended claims.

The invention claimed is:

1. A method for treating a set of symptoms corresponding to a neurological disorder exhibited by a patient, comprising: 10

determining a first set of neural stimulation parameters capable of treating a first subset of symptoms, with the first set of neural stimulation parameters including a first frequency;

determining a second set of neural stimulation parameters 15 capable of treating a second subset of symptoms, with the second set of neural stimulation parameters including a second frequency; and

applying a neural stimulation therapy based upon the first set of neural stimulation parameters and the second set 20 of neural stimulation parameters to the patient, wherein the neural stimulation therapy is applied in accordance with a frequency function that includes the first and the second frequencies.

2. The method of claim 1, wherein the neural stimulation 25 therapy includes a frequency function that sweeps between the first and the second frequencies.

3. The method of claim 1, wherein the first subset of symptoms responds to neural stimulation more rapidly than 30 the second subset of symptoms.

4. The method of claim 1, further comprising positioning a set of electrodes with respect to a target neural population within the patient.

5. The method of claim 4, wherein at least one electrode 35 within the set of electrodes is configured to deliver neural stimulation therapy to a cortical region within the patient.

6. The method of claim 5, wherein the cortical region corresponds to a neural population that facilitates control of at least one type of patient movement.

7. A method for treating a set of symptoms corresponding 40 to a neurological disorder exhibited by a patient, comprising:

14

applying a first neural stimulation signal having a first frequency to the patient to treat a first subset of symptoms; and

applying a second neural stimulation signal having a second frequency to the patient to treat a second subset of symptoms, wherein the first neural stimulation signal is applied during a first time interval and the second neural stimulation signal is applied during a second time interval, and wherein the first and second time intervals depend upon a severity of the first subset of symptoms relative to the second subset of symptoms.

8. The method of claim 7 wherein:

applying a first neural stimulation signal includes applying the first neural stimulation signal to the patient in a continuous or generally continuous manner during the first time interval; and

applying a second neural stimulation signal includes applying the second neural stimulation signal to the patient in a noncontinuous or interrupted manner following the first time interval.

9. The method of claim 8:

wherein the second neural stimulation signal provides an extent of relief from a subset of patient symptoms that is (a) generally identical to an extent of relief from the subset of patient symptoms provided by the first neural stimulation signal, or (b) acceptable relative to an extent of relief from the subset of patient symptoms provided by the first neural stimulation signal, or both (a) and (b).

10. The method of claim 7, wherein the first time interval is greater than approximately one week.

11. The method of claim 7, wherein the first time interval is approximately one month.

12. The method of claim 7, wherein the second neural stimulation signal includes continuous or generally continuous neural stimulation during the patient's waking hours.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,236,830 B2
APPLICATION NO. : 10/317002
DATED : June 26, 2007
INVENTOR(S) : Gliner

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On page 3, under Item 56 "Other Publications", in column 2, line 56, delete "suppressess" and insert -- suppresses --, therefor.

On page 4, under Item 56 "Other Publications", in column 1, line 67, delete "Potenetiation" and insert -- Potentiation --, therefor.

On page 4, under Item 56 "Other Publications", in column 2, line 73, delete "softwre" and insert -- software --, therefor.

On page 5, under Item 56 "Other Publications", in column 2, line 40, delete "iss." and insert -- iss. --, therefor.

In column 6, lines 46-47, delete "Electroencephalograpy" and insert -- Electroencephalography --, therefor.

Signed and Sealed this

Seventh Day of October, 2008

A handwritten signature in black ink, reading "Jon W. Dudas". The signature is stylized with a large, looped initial "J" and a cursive "Dudas".

JON W. DUDAS
Director of the United States Patent and Trademark Office